Journal: bioRxiv

Article Title: Towards the Clinical Translation of a Silver Sulfide Nanoparticle Contrast Agent: Large Scale Production with a Highly Parallelized Microfluidic Chip

doi: 10.1101/2023.12.02.569706

Figure Lengend Snippet: Schematic and photographs showing microfluidic chips used for synthesis of Ag 2 S-NP.

Article Snippet: A commercially available staggered herringbone single channel microfluidic chip was purchased from Microfluidic ChipShop (Jena, Germany).

Techniques:

Journal: Biomicrofluidics

Article Title: “Learning on a chip:” Microfluidics for formal and informal science education

doi: 10.1063/1.5096030

Figure Lengend Snippet: Microchannel fabrication techniques. (a) Shrink-film generation of masters for PDMS devices. (Top) Laser-printed polyolefin sheets shrink biaxially by 95%. (Bottom) PDMS is cured on the polyolefin master. Adapted with permission from Nguyen et al., Biomicrofluidics 5(2), 022209 (2011). Copyright 2011 AIP Publishing LLC. (b) Laminate microfluidic device from laser-cut tape and acrylic sheets. Acrylic (blue) layers are cut to define the channels and adhesive tape (yellow) is used to laminate the layers together. Reproduced with permission from Gerber et al., Biomicrofluidics 9(6), 064105 (2015), Copyright 2015 AIP Publishing LLC. (c) Print-cut-laminate fabrication method. (i) Polyester sheets with adhesive toner (blue) and hydrophilic valves (black) as well as cut channels are assembled on a guide scaffold. (ii) A conventional office laminator is used to laminate the sheets together into (iii) a single device. (iv) A completed PCL device for centrifugal microfluidics. Adapted from Thompson et al., Nat. Protoc. 10, 875–886 (2015). Copyright 2015 Springer Nature. (d) 3D printed masters for PDMS chips. (Left) A CAD rendering of a chip master showing a serpentine microfluidic channel, posts for tubing connections, and a lip to create a trough for casting PDMS. (Right) A completed PDMS devices. Adapted with permission from Comina et al., Lab Chip 14(2), 424–430 (2014). Copyright 2014 The Royal Society of Chemistry. (e) ESCARGOT method for creating channels in PDMS. (Top) 3D printed ABS scaffolds are submerged in PDMS, which is then cured. Acetone is then used to dissolved the ABS scaffold, resulting in a network of microchannels. (Bottom) Complex architectures such as spirals (blue) around a single channel (red) are possible. Adapted from V. Saggiomo and A. H. Velders, Adv. Sci. 2(9), 1500125 (2015). Copyright 2015 Author(s), licensed under a Creative Commons 4.0 License. (f) Modular LEGO® microfluidic system. (Left) Different building blocks are engraved with different functionalities and can be snapped together on a LEGO® baseplate. (Right) Microfluidic modules are formed from channels milled into the side of a LEGO® brick, which are sealed with a sealing film. An O-ring ensures a tight connection with an adjacent module. The post allows bricks to be snapped together with a third brick or plate. Adapted with permission from C. E. Owens and A. J. Hart, Lab Chip 18(6), 890–901 (2018). Copyright 2018 The Royal Society of Chemistry.

Article Snippet: However, though costs decrease with scale, these chips are still relatively expensive. (e.g., at the time of writing, a simple single channel chip design is listed as €36.20 each from the Microfluidic Chip Shop, www.microfluidic-chipshop.com .

Techniques: Adhesive

Journal: Communications Biology

Article Title: Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response

doi: 10.1038/s42003-021-02526-y

Figure Lengend Snippet: a Components of the microfludic set up. Air and CO 2 from the wall lines (WL) are mixed in airflow mixer (AFM) and passed through air filter (AF) before reaching the pump (OB1-MK3). Flow path 1 (FP1) with air splitter (ASpl) shows eight outlets connected to the reservoirs with specific drug concentrations. Time and flow rate of the reservoir content are regulated by the distributor (MUX) and piezo pump (OB1-MK3). The FP1 continues to a bubble trapper (BT) and a digital flow sensor (DFS) into 2 chained Ibidi chips (ICh 1,2) and finaly to the waste bottle (WBot). Flow path 2 (FP2) for mock treated spheroids is represented by single reservoir and the two chained Ibidi chips (ICh 3,4). A feedback loop (FL) connects each digital sensor (DFS) to the OB1-MK3 pump to maintain desired flow rate. b Photograph of the Ibidi Luer chip with 8 Matrigel encapsulated spheroids, and brighfield microscopic image of SW620 spheroid after 7 days of continuous media flow. Scalebar = 100 µm.

Article Snippet: This platform includes a single channel microfluidic Ibidi chip (Ibidi GmbH, Germany), that we adapted to handle eight tumour spheroids encapsulated in Matrigel droplets.

Techniques:

Journal: Communications Biology

Article Title: Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response

doi: 10.1038/s42003-021-02526-y

Figure Lengend Snippet: In vivo free drug plasma concentrations (determined by LC-mass spectrometry and population-based PK model) and mimicked concentrations in the microfluidic setup.

Article Snippet: This platform includes a single channel microfluidic Ibidi chip (Ibidi GmbH, Germany), that we adapted to handle eight tumour spheroids encapsulated in Matrigel droplets.

Techniques: In Vivo, Clinical Proteomics, In Vitro

Journal: Communications Biology

Article Title: Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response

doi: 10.1038/s42003-021-02526-y

Figure Lengend Snippet: a , b In static plate format, SW620 tumour spheroids were exposed to a fixed dose corresponding to the maximum mouse plasma concentration achieved with 50 mg/kg dose of irinotecan (SN38 Cmax 5.5 nM), and 10 mg/kg AZD0156 (Cmax 192 nM) continuously for 6 days. In microfluidic Ibidi chip, tumour spheroids were exposed to eight different concentrations in a gradient fashion mimicking the in vivo pharmacokinetic profile and treatment schedule for both drugs. c Spheroids were imaged in situ (plate/chip) at the end of the treatment and their volumes calculated from average radius deducted from min/max Feret. d Spheroid viability was measured at the end of the treatment by CellTiterGlo assay ( d ). N = 6 per condition from two independent experiments. Box-plots show median (centre line); box limits are 25th to 75th percentile; whiskers represent min and max values. Statistical analysis was performed using 1-way ANOVA.

Article Snippet: This platform includes a single channel microfluidic Ibidi chip (Ibidi GmbH, Germany), that we adapted to handle eight tumour spheroids encapsulated in Matrigel droplets.

Techniques: Clinical Proteomics, Concentration Assay, In Vivo, In Situ

Journal: Communications Biology

Article Title: Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response

doi: 10.1038/s42003-021-02526-y

Figure Lengend Snippet: Spheroids were treated in the chip with SN38 and AZD0156 at different schedules using the microfluidic setup. Spheroids were recovered from the chip at day 7 and DNA double strand break damage was assessed via the presence of γH2AX. Scalebar = 100 µm. a Representative images of nuclei (blue/Hoechst 33342) and γH2AX (green), b quantification of γH2AX positive cells. (A-SN38, B-SN38 + AZD0156 3/7 with 24 h gap, C-SN38 + AZD0156 3/7 with 72 h gap, D-SN38 + AZD0156 1/7, E-SN38 + AZD0156 7/7, F-control). Cleaved caspase 3 (CC-3) was used to quantified apoptotic cell death ( c ), and Ki67 to measure the effect on proliferation ( d ). N ≥ 5 per condition from two independent experiments. Box-plots show median (centre line); box limits are 25th to 75th percentile; whiskers represent min and max values. Statistical analysis was carried out using 1-way ANOVA, Tukey’s multiple comparisons, CI = 95%, **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.1.

Article Snippet: This platform includes a single channel microfluidic Ibidi chip (Ibidi GmbH, Germany), that we adapted to handle eight tumour spheroids encapsulated in Matrigel droplets.

Techniques: Control

Journal: Communications Biology

Article Title: Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response

doi: 10.1038/s42003-021-02526-y

Figure Lengend Snippet: SW620 tumour spheroids were treated with SN38 and two different gapped schedules with the ATM inhibitor in Ibidi microfluidic chip using 8-concentration profile over 24 h (Table ), spheroids volumes were evaluated at day 7 of post-treatment. N ≥ 5 per condition from two independent experiments. Box-plots show median (centre line); box limits are 25th to 75th percentile; whiskers represent min and max values ( a ); SW620 tumour xenografts were subcutaneously implanted in mice ( N = 15 per group) and subjected to the same treatment schedules as the spheroids in Ibidi chip. Tumour volume was measured regularly over 40 days. The graph represents mean ± SE. Tumour volumes at days 7, 15 and 35 were plotted as box-and-whisker graphs for easier comparison with in vitro microfluidic data (median—centre line; box limits—25th to 75th percentile; whiskers—min and max values) ( b ). Statistical analysis was carried out using 1-way ANOVA, Tukey’s multiple comparisons, CI = 95%, **** p < 0.0001; *** p < 0.001; ** p < 0.01; * p < 0.1.

Article Snippet: This platform includes a single channel microfluidic Ibidi chip (Ibidi GmbH, Germany), that we adapted to handle eight tumour spheroids encapsulated in Matrigel droplets.

Techniques: Concentration Assay, Whisker Assay, Comparison, In Vitro

Journal: Communications Biology

Article Title: Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response

doi: 10.1038/s42003-021-02526-y

Figure Lengend Snippet: Treatment schedules for SN38 and AZD0156 assessed in the microfluidic setup, on Matrigel-encapsulated SW620 spheroids.

Article Snippet: This platform includes a single channel microfluidic Ibidi chip (Ibidi GmbH, Germany), that we adapted to handle eight tumour spheroids encapsulated in Matrigel droplets.

Techniques: